• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of aemPermissionsJournals.ASM.orgJournalAEM ArticleJournal InfoAuthorsReviewers
Appl Environ Microbiol. Mar 2005; 71(3): 1356–1363.
PMCID: PMC1065133

Differential Activities of Four Lactobacillus casei Promoters during Bacterial Transit through the Gastrointestinal Tracts of Human-Microbiota-Associated Mice


In a previous study using fusion of the deregulated lactose promoter lacTp* and reporter genes, we suggested that Lactobacillus casei could initiate de novo protein synthesis during intestinal transit. In order to confirm this finding and extend it to other promoters, we adopted a reverse transcriptase quantitative PCR (RT-QPCR) approach combined with a transcriptional fusion system consisting of luciferase genes under the control of four promoters (ccpA, dlt, ldh, and lacT*) from L. casei DN-114 001. Promoter expression was monitored during cell growth, and variable luciferase activities were detected. In 3-day cultures, all the genetically modified strains survived but without exhibiting luciferase activity. Luciferase mRNA levels determined by RT-QPCR analysis (RNA/CFU) were not significant. The cultures were administered to human-microbiota-associated mice, and the feces were collected 6 h later. L. casei promoters lacTp* and ldhp initiated mRNA synthesis during gastrointestinal transit. The promoters, ccpAp and dltp, exhibited no luciferase activity, nor was de novo-synthesized luciferase mRNA detected in the feces. L. casei seems to adapt its physiology to the gastrointestinal tract environment by modulating promoter activities. The approach (fecal transcriptional analysis) described herein may, moreover, be of value in studying gene expression of transiting bacteria in human fecal specimens.

Lactobacillus casei has attracted considerable interest as a probiotic over the last few years (15, 19). The strain L. casei DN-114 001 has been shown to alleviate acute diarrhea in healthy children (21, 22), to modulate the production of proinflammatory cytokines in Crohn's disease ex vivo (3), and to enhance the immune system during bacterial gastrointestinal (GI) transit (20). However, little is known about the survival of L. casei species and their physiological status in the environment of the GI tract.

Probiotics are usually ingested with fermented milk during the late stationary phase of the bacterial cycle. At the onset of the stationary phase, the overall rate of protein synthesis has been shown to drop precipitously to a rate equivalent to approximately 0.2% of the exponential growth rate (13). These changes are concomitant with a decrease in overall mRNA and DNA synthesis (13). The behavior of such metabolically inactive cells in the GI environment was thus investigated with a view to identifying the mechanisms underlying their action on health.

To carry out this work, we developed a genetic approach using transcriptional fusion of luciferase genes (luxA and luxB) and selected promoters to study the response of lactic acid bacteria to the GI tract environment (5). The same approach was then extended to a probiotic microorganism, L. casei DN-114 001, to study its response to the GI tract in the human-microbiota-associated (HMA) mouse model using transcriptional fusion of the modified L. casei lacTEGF operon promoter and luxA and luxB genes from Photorhabdus luminescens. Resulting data suggest that L. casei can initiate de novo protein synthesis during transit with the diet (18). However, determining luciferase activity necessitates both enzyme synthesis and the environmental conditions required for luciferase activity (FMNH2 availability, pH). The aims of the present study were to validate results previously obtained with transcriptional fusion (18) by quantifying luciferase mRNA in the GI tract while investigating the activity of other L. casei promoters in the GI tract.

A sensitive and easy-to-perform method of quantifying L. casei mRNA in culture and fecal samples was developed. Four L. casei promoters involved in different metabolic pathways were selected among promoter sequences available in GenBank: the deregulated lactose operon promoter (lacTp*) (1, 18), the promoter of l-(+)-lactate dehydrogenase (ldhp) (25), the ccpA promoter (ccpAp) (16), and the dlt operon promoter (dltp) (17).

Protein CcpA is a central catabolite regulator expressed constitutively in L. casei cultures (16). Some researchers (16), however, accept the possibility of autoregulation of its synthesis. The dlt operon is necessary for cell growth in L. casei, as its inactivation generates defective cell separation and aberrant morphology (17) and its promoter has been reported to be weak in a gram-positive bacterium (26). In Bacillus subtilis, peak expression of the dlt operon occurs during logarithmic growth prior to down-regulation by the SpoOA and AbrB global regulators (23). In L. casei, the promoter ldhp is known to be a highly efficient and constitutive promoter (25). In Lactobacillus helveticus, the ldh gene is strongly expressed in the logarithmic phase, but in the stationary phase, the level of ldh transcripts decreases rapidly (30).

Direct quantitative transcript analysis of fecal extracts from HMA mice confirmed that L. casei can initiate mRNA synthesis during transit through their GI tracts (18). Moreover, differential activities of the four promoters were detected in the GI environment.


Bacterial strains, media, and animals.

Table Table11 shows the bacterial strains and plasmids used in this study. Escherichia coli strains LLB1 and TG1 RepA were cultured aerobically in Luria-Bertani medium at 37°C. L. casei strains, derived from strain DN-114 001 (Collection Nationale de Culture de Microorganisms no. I-1518), were cultured in MRS medium at 37°C (6). When required, the concentrations of antibiotics added to the media were 100 μg of ampicillin (ICN)/ml or 100 μg of erythromycin (Merck, Darmstadt, Germany)/ml to select E. coli transformants and 5 μg of erythromycin/ml or 5 μg of chloramphenicol (ICN)/ml for L. casei. For transcription inhibition studies, a concentration of 100 μg of rifampin (Merck)/ml was used. The HMA mice used in this study were obtained as previously described (18).

Bacterial strains and plasmids used in this study


The method for plasmid and genomic DNA extraction was based on that of Sambrook et al. (29). Restriction endonucleases and T4 DNA ligase were obtained from Fermentas (Vilnius, Lithuania). Taq DNA polymerase was obtained from Takara Bio, Inc. (Otsu Shiga, Japan). All the enzymes were used per the manufacturers' instructions. L. casei was transformed by electroporation using a Gene-Pulser apparatus (Bio-Rad Laboratories, Richmond, Calif.) as previously described (24).

Plasmid and strain constructs.

Transcriptional fusions of three promoters from L. casei DN-114 001, ccpAp, dltp, and ldhp, fused to P. luminescens luxA and luxB genes were constructed and incorporated in the chromosome of L. casei DN-114 001 (Table (Table11 and Fig. Fig.1).1). For the integrative transcriptional fusion with luciferase genes, pIL4242 was first constructed. This plasmid consists of luxA and luxB genes inserted into pOri. In this integrative vector, the luxA and luxB genes are followed by the E. coli rrnB terminator sequence and RepA protein, produced in trans, is required for it to replicate in E. coli or L. casei. The three promoters were PCR amplified (Table (Table2)2) and fused upstream of the luciferase genes in pIL4242. The final integrative plasmids, pDN75, pDN76, and pDN77, contained, respectively, the promoters ccpAp, dltp, and ldhp (Table (Table11 and Fig. Fig.1).1). These plasmids were integrated as previously described (18) in the DN-114 001 chromosome by homologous recombination. The corresponding strains are listed in Table Table1.1. The integrants were analyzed by PCR using primers located in the related genes and in luxB. The correct insertions of ccpAp::luxAB, dltp::luxAB, and ldhp::luxAB were checked using primer pairs OLC33-OLC52, OLC33-OLC71, and OLC33-OLC72, respectively. The degenerated primers, OLC71 and OLC72 (Table (Table2),2), were designed by homologous sequence analysis of dlt and ldh genes from several lactic acid bacteria. The DN-240 041 (lacTp*::luxAB) strain had previously been constructed (18).

FIG. 1.
Genetic constructs. Step 1: Promoter insertion in pBluescript II SK(+). XbaI-SmaI-cut PCR ccpA and dlt promoter or EcoRI-BamHI for ldh was used. This fragment was inserted into the XbaI-SmaI or EcoRI-BamHI sites of pBluescript II SK(+), ...
Primers used in this study

Luminescence determination. (i) Measurement in culture.

To demonstrate that pH interferes with luciferase activity, overnight L. casei cultures in MRS medium did not exhibit luminescence but a 10-fold dilution of the same culture in fresh medium immediately generated luciferase activity (7). The initial method of measuring luminescence was therefore modified (5): the cultures in MRS medium were systematically diluted 1:10 in fresh medium, and luciferase activity was determined within less than 1 min, immediately after the addition of 5 μl of decanaldehyde (Sigma, Detroit, Mich.) to 1 ml of diluted broth culture (5). Light emission was measured in a Luminometer (LB9501; Berthold, Bad Wilbad, Germany) in arbitrary units, relative light units (RLU).

(ii) Measurement in fecal samples.

Feces were rapidly 10-fold diluted in saline buffer after sampling. Luciferase measurements were then immediately performed on 1 ml of diluted fecal samples after addition of 5 μl of decanaldehyde.

(iii) Luciferase activity expression.

For growth kinetics, luciferase activities in RLU were divided by values of absorbance determination at 600 nm (A600) so that luciferase activities were expressed as RLU per A600. For the comparison of luciferase activity in the inoculum and feces, the luciferase activities in RLU were divided by the number of CFU determined at the same time in each sample. The values were multiplied by 106 so that results were expressed as log μRLU per CFU.

Growth kinetics.

MRS medium was inoculated with 1% 2-day-old L. casei culture. The cultures were incubated at 37°C. Samples were collected at regular intervals and 10-fold diluted for A600 (model 6400 spectrophotometer; Jenway, Dunmow, Essex, United Kingdom), luminescence determination (LB9501; Bertold), and agar plate count of the bacteria.

Study of promoter activities.

L. casei DN-240 041, DN-240 047, DN-240 048, and DN-240 049 cultures in MRS medium were incubated at 37°C for 3 days. The inoculum size was selected so that the cultures obtained were in exponential phase after 1 day. For each strain, bacterial viability and promoter activity were determined daily in culture and posttransit through the GI tracts of HMA mice. Promoter activities were studied by luciferase activity determination and luciferase mRNA quantification. Culture samples were diluted 1:10 in prewarmed medium containing erythromycin and incubated at 37°C. The experiment was carried out with or without the addition of rifampin to the media. Counts and luminescence determinations were performed over a period of 4 h postdilution. HMA mice were orally administered about 0.5 ml of L. casei culture at time zero. The feces were individually collected 6 h later. Counts, luminescence determination, and RNA extraction were performed on feces diluted 1:10 in saline buffer.

RNA extraction.

The protocol developed was based on the isolation of the bacterial fraction from feces or broth culture followed by cell lysis and chloroform-phenol extraction.

(i) Fecal samples.

A total of 0.1 g of the freshly collected fecal sample was resuspended in 1 ml of Tris-EDTA (TE). The suspension was centrifuged at 500 × g for 1 min (Sigma 3K15) to remove the fiber. The supernatants were transferred to new tubes and then filtered (5-μm pore size; Millipore) to remove small particles. The effectiveness of bacterial fraction isolation was estimated by total plate counts conducted on the suspension of freshly collected fecal samples and on the supernatants containing the microbial fraction by using MRS-erythromycin medium. The filtrate, containing about 80% of the microbial fraction, was centrifuged at 7,000 × g and 4°C for 2 min. The supernatant was eliminated, and the pellet was washed twice and resuspended in 100 μl of TE. The RNA was then extracted as described below.

(ii) Culture samples.

Cultures were centrifuged at 7,000 × g and at 4°C for 2 min. The pellets were washed twice and suspended in 100 μl of TE. The RNA was isolated using the Macherey Nagel kit (Nucleospin RNAII) per the manufacturer's instructions but with modifications and partially adapted steps: 350 μl of buffer RA1 (supplied with the kit), 5 μl of β-mercaptoethanol, and 300 mg of glass beads (each ≤106 μm in diameter; Sigma) were added to the resuspended bacteria. The tubes containing the glass beads were shaken twice at 4,500 rpm for 40 s in a Fast Prep instrument (FP 120, Bio101; Savant, Holbrook, N.Y.) with rapid cooling on ice between steps. After shaking, the tubes were centrifuged at 7,000 × g for 5 min. The supernatants were transferred to new tubes, and extraction was conducted per the manufacturer's protocol. The RNA was rapidly subjected to chloroform-phenol extraction and ethanol precipitation. The pellets were washed with 70% ethanol and resuspended in 60 μl of RNase-free water. Genomic DNA contamination was removed by DNase treatment (DNA free; Ambion Europe).

In vitro synthesis of luciferase messenger.

The P. luminescens gene encoding luxA was PCR amplified from plasmid pIL4242 with primers OLC15 and OLC16. The PCR product was ligated to a T7 phage promoter adapter (Lig'nScribe; Ambion Europe). The ligation product was used in subsequent PCR amplification with the T7-promoter-specific primer P1 (supplied with the kit) and OLC16 to generate a sense strand transcription template. The T7-driven in vitro transcription reaction was performed using a standard transcription assay (MEGAscript; Ambion Europe). The synthetic luciferase RNA was quantified using a spectrophotometer (Biophotometer; Eppendorf) and stored at −80°C. The concentrated RNA was diluted for the reverse transcriptase quantitative PCR (RT-QPCR) assays.

Reverse transcription.

First-strand cDNA synthesis was conducted with random hexamers (New England Biolabs) by using 0.25 to 0.50 μg of DNase I-treated total RNA. For each experiment, 10-fold dilutions (105 to 109 copies/μl) of in vitro-transcribed luciferase RNA were reverse transcribed concomitantly with the samples to generate QPCR standard curves. For the RT assays, Moloney murine leukemia virus RT (Invitrogen) was used per the manufacturer's instructions. Negative controls without RT were conducted for all samples in order to exclude any genomic DNA contamination.

SYBR green QPCR.

In order to assess promoter activity during the GI transit of L. casei, real-time QPCR was conducted on samples. Luciferase messenger quantification was performed on an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems). Primer Express version 1.0 from Applied Biosystems was used to design luciferase primers. A 198-bp PCR fragment generated by using primers OLC15 and OLC32 was selected for all the assays (see Results section). QPCR was conducted on 10 μl of 10-fold-diluted reverse-transcribed cDNA and 15 μl of 1× PCR mix (SYBR green I PCR core kit; Applied Biosystems) with optimum concentrations of primers. The thermal cycling conditions were as follows: 2 min at 50°C and then 10 min at 95°C followed by 40 cycles, with 1 cycle consisting of 15 s at 95°C and 1 min at 60°C. For each run, a standard dilution of a luciferase reverse-transcribed RNA fragment containing a known quantity was included for cDNA quantification. A linear relationship was obtained by plotting the threshold cycle against the logarithm of a known amount of initial luciferase RNA. The equation of the best-fit line was determined by linear regression analysis. The plotting made it possible to determine QPCR effectiveness. The quantities of target copies contained in an unknown sample were determined by extrapolation from the linear regression of the standard curve. A negative control (no template control) and RNA samples which had not undergone the RT step (RT) were included in each run. For each cDNA quantification, the number of copies was determined in triplicate and the mean was used for analysis. The specificity of the PCR was checked by analyzing the reaction mixtures by using 3% agarose gel electrophoresis.

Repeatability and relative gene expression.

For all the promoters, the experiments were conducted in duplicate or triplicate using three mice per experiment. Six to nine mice were thus used to determine the activity of each promoter following HMA GI transit. Only samples with a constant total RNA concentration between 0.25 and 0.50 μg/μl were used for RT-QPCR (approximately 80% of the samples). Concomitantly with RNA isolation, L. casei cells were counted on MRS-erythromycin cultures. For each sample, the number of cDNA copies (an indicator of mRNA quantity) was divided by the number of bacterial CFU (mRNA/CFU).


In vitro luciferase expression in L. casei under the control of various promoters. (i) Luciferase activities during L. casei multiplication.

The growth of each constructed strain was monitored in triplicate over a 24-h period by A600 determination (Fig. (Fig.2A).2A). The exponential growth phase continued to an A600 of about 5.0. The calculated generation times were 2.25 h for DN-240 041 (lacT*), 2.5 h for DN-240 049 (ldh) and DN-240 048 (dlt), and 2.75 h for DN-240 047 (ccpA). In the cultures, luciferase activities of the four promoters were very different (Fig. (Fig.2B).2B). The highest activity was observed with the ldh promoter (ldhp) (3 × 105 RLU/A600), while the activity of the modified lacT* promoter (lacTp*) was threefold lower. The activities detected with the ccpA and dlt promoters (ccpAp and dltp) were, respectively, 8 and 25 times lower than that of ldhp but markedly above the limit of detection. The relative luciferase expressions per CFU were 2.7, 2.2, 1.8, and 1.3 log μRLU/CFU for DN-240 049 (ldh), DN-240 041 (lacT*), DN-240 047 (ccpA), and DN-240 048 (dlt), respectively. For all of the promoters, the highest luciferase activity was observed during early exponential growth. A gradual decline subsequently occurred. Luminescence declined during the switch from the mid- to late-exponential-growth phase (A600 = 1.5 to 2.0). No luciferase activity was detected during the stationary phase (A600 of about 5).

FIG. 2.
L. casei growth and promoter activities in MRS medium. Strains DN-240 041 (lacT*, triangles and solid lines), DN-240 049 (ldh, squares and dotted lines), DN-240 048 (dlt, squares and solid lines), and DN-240 047 (ccpA, triangles and dotted lines) ...

(ii) Luciferase activities from 3-day-old L. casei cultures.

We sought to determine, in culture, the minimal time for restarting luciferase activity from 3-day-old cultures. The four constructed strains were cultured for 3 days and then diluted in fresh medium, and the luciferase activity was monitored over a 3.5-h period (Table (Table3).3). During that short interval, no significant multiplication was detected (data not shown), as had already been observed (18). However, luciferase activity was resumed more rapidly by DN-240 049 (ldh) and DN-240 041 (lacT*) (after 2 h) than by DN-240 047 (ccpA) and DN-240 048 (dlt) (3.5 h). For all the genetic constructs, the addition of rifampin blocked luciferase activity without affecting L. casei viability.

Luciferase activities of 3-day-old L. casei cultures diluted in fresh mediuma

(iii) Luciferase activity under the control of different promoters in HMA mice.

The strains expressing luciferase under the control of ldhp and ccpAp were incubated for 3 days in MRS medium. On days 1, 2, and 3, HMA mice were orally administered the culture and luciferase activity/CFU was estimated in the dosing preparation and mouse feces 6 h postdosing (Fig. (Fig.3).3). On days 2 and 3, no luciferase activity was detected in the dosing preparation but resumption of activity was observed in the feces. Posttransit, the luciferase expression induced by the ldh promoter was about fivefold greater than that induced by ccpAp.

FIG. 3.
Analysis of luciferase expression in L. casei post-HMA mouse GI transit. The mice were orally administered 0.5 ml of a preparation containing L. casei (108 to 109 CFU/ml) culture and spores (same quantity) of B. subtilis (transit marker) daily at 10 a.m. ...

The same experiment with the four transcriptional fusion constructs was repeated using a 3-day-old bacterial culture and testing in HMA mice (Table (Table4).4). Posttransit luciferase activity resumption was observed for DN-240 049 (ldh) and DN-240 041 (lacT*) but not detected with the other promoters.

Analysis of the expression of the four promoters in 3-day-old cultures and post-HMA mouse GI transita

Use of RT-QPCR to determine luciferase mRNA in L. casei. (i) Reproducibility of RNA isolation and use of a synthetic luciferase RNA standard.

RNA isolation was determined on 0.1 g of feces containing 107 to 108 L. casei. The effectiveness of extraction from a larger (1 g) fecal sample was inferior (data not shown). Repeated RNA extraction from 0.1 g of HMA mouse fecal samples consistently generated similar results, demonstrating the satisfactory between-assay reproducibility of the method (325 ± 40 ng/μl). The chloroform-phenol-treated total RNA remained stable when stored at −80°C. With respect to pure cultures, reproducible quantities of RNA were obtained from 108 to 109 bacteria. After further DNase treatments, samples that had not been reverse transcribed (RT) showed no amplification, indicating the absence of contaminating genomic DNA.

In order to plot standard RNA curves, specific luciferase RNA was synthesized in vitro. The in vitro transcription yield ranged from 1011 to 1012 copies of synthetic RNA per microliter. This was verified to assure that PCR effectiveness did not fluctuate with the initial amount of RNA. In order to ensure that the experimental conditions were the same for both the standards and the samples during RT-QPCR and in order to consider the rate of the RT step, synthetic luciferase RNA was used for the standard curves (8).

(ii) Adaptation of real-time QPCR to the digestive tract contents for L. casei mRNA quantification.

In order to confirm the results obtained in previous work based on luciferase activities (18), L. casei gene expression was quantified by adapting a sensitive and accurate method for use on the contents of the GI tract. RT-QPCR was selected on the basis of the small quantity of total RNA it required compared to other methods, such as Northern hybridization. To detect the expression of the four genes against a high endogenous microbiota mRNA background, a fragment of the luciferase genes which had previously been fused with the promoters of interest was targeted in RT-QPCR. Since luciferase genes were absent from the HMA mice GI tract, the transcriptional fusion approach made the specific quantification of promoter activity possible. Real-time PCR assays were conducted using the DNA-binding dye SYBR green I. For the five pairs of primers tested, satisfactory results were obtained with the OLC15-OLC32 pair. PCR effectiveness was around 81.2%, and no primer dimmer artifacts for the negative control were observed. All of the RT-QPCR products yielded a single band of the expected magnitude on agarose gel. The specificities of the signals detected from GI tract contents in RT-QPCR were confirmed (data not shown) with HMA mice not exposed to luciferase-containing L. casei. The limit of detection for mRNA molecules per number of CFU was about 10 copies of luciferase mRNA per CFU.

(iii) Direct analysis of luciferase transcripts post-GI transit.

The between-assay variability of messenger quantification for the DN-240 049 strain is shown in Table Table5.5. Two different experiments performed on six mice (three per experiment) generated reproducible results with 15.8% variability (Table (Table5).5). The expression levels of the four genes of L. casei post-GI transit, determined by RT-QPCR, are summarized in Fig. Fig.33 and Table Table4.4. For each gene, the expression level was determined in six to nine mice. The number of luciferase mRNA copies quantified by RT-QPCR posttransit was compared to that present in the initial dosing preparation (Fig. (Fig.33 and Table Table4).4). After 2 days of incubation at 37°C, luxA and luxB transcripts were detected by RT-QPCR in 2-day-old L. casei cultures in MRS medium while no luciferase activity was detected (Fig. (Fig.3).3). For strains DN-240 049 (ldh) and DN-240 047 (ccpA), the number of mRNA copies was almost the same in the 2-day-old cultures (96 and 26 copies/CFU, respectively) and posttransit in the feces (84 and 30 copies/CFU, respectively) (Fig. (Fig.3).3). In consequence, 3-day-old cultures were used to investigate de novo protein synthesis in the GI tract. In these cultures, the viable bacteria count was around 109 CFU/ml (Table (Table4).4). For all strains, the number of luciferase mRNA copies per CFU was below the level of detection in 3-day-old cultures (Table (Table4).4). In the 3-day-old posttransit cultures, a marked increase in luciferase transcripts was detected for DN-240 049 (ldh) (27 copies/CFU) and DN-240 041 (lacT*) (118 copies/CFU), reflecting de novo synthesis (Table (Table4).4). For DN-240 047 (ccpA) and DN-240 048 (dlt), no signal was detected by RT-QPCR on the posttransit fecal samples (Table (Table4).4). These results confirm and reinforce those obtained by luminescence determination.

Variability of luciferase mRNA quantities in HMA mouse fecesa


This study was designed to investigate the physiological status of a probiotic bacterium, L. casei DN 114 001, during GI transit. In a previous study (18), we used transcriptional fusion of luxA and luxB genes and the lacT* promoter to demonstrate that L. casei does not multiply in the HMA mouse GI tract model but that it does survive. The comparison of the luciferase activity of 3-day-old cultures, preingestion versus posttransit, together with protein synthesis inhibition in cultures suggests that L. casei can initiate de novo protein synthesis during GI transit with the diet. In the previous study, one promoter was investigated and the evidence of de novo synthesis in the GI tract was indirect. The present study went into greater depth by using four L. casei promoters suspected of exhibiting different degrees of effectiveness in vitro. The activity ranking determined in vitro (ldhp > lacTp* > ccpAp > dltp) was consistent with that reported in previous studies (16, 25, 26). Moreover, a molecular approach consisting of RT-QPCR was applied to the transcriptional fusion constructs to clearly show de novo mRNA synthesis by bacteria during GI transit.

Use of RT-QPCR has rendered investigation of in vivo gene expression during infectious processes possible (28, 31). The application of QPCR methods to GI contents has mainly focused on the detection or quantification of exogenous bacterial genomes (2, 11), while transcriptional analysis has not previously been addressed. The molecular approach developed for this study made quantification of specific mRNA in a fecal extract possible for the first time. In order to detect the expression of the four genes against a high background level of endogenous microbiota mRNA (32), a fragment of the luciferase genes previously fused with the promoters of interest was targeted in RT-QPCR. The luxA and luxB genes were absent from the HMA mouse GI tract. It was thus possible to quantify the luciferase messengers specifically and estimate promoter activities in a different manner. Since analysis at transcriptional level does not necessarily indicate whether luciferase proteins are synthesized in the GI tract, this approach was combined with luminescence determination.

When mice were administered 2-day-old culture preparations, the luciferase activity determinations showed potential de novo synthesis in the GI tract for three promoters. These results were not, however, confirmed by mRNA analysis. Although luciferase mRNA remained present in these cultures, luciferase activity was not detected. The presence of detectable mRNA about 10 to 20 h after the onset of the stationary phase, in line with previous studies (33), suggests that the luciferase activity detected posttransit may originate from enzymes already synthesized before ingestion. In this context, the RT-QPCR approach generated further information to combine with the luciferase determinations. Hence, the absence of luciferase activity in 3-day-old cultures was shown to be concordant with the nonsignificant level of luciferase messengers detected. The facts that no luciferase mRNA was present in the initial 3-day-old culture and that luciferase activity regeneration was prevented by RNA polymerase inhibition suggest that the detection of luminescence is clearly concomitant with de novo mRNA synthesis. The L. casei cells were metabolically inactive when administered to the mice. During intestinal transit, they produced luminescence and therefore proceeded to de novo synthesis under the control of the ldh and lacT* promoters. These results were confirmed by direct in vivo transcription analysis. The positive activities of the deregulated lacT* and ldh promoters in the GI tract strongly suggest that at least the primary basal metabolism of the bacteria is activated during transit. However, exposure to the GI environment involves physiological adaptation, since functions unnecessary for basal metabolism (ccpA and dlt promoters) were not activated. L. casei does not multiply in the GI tract (18). It is therefore consistent that the bacterium does not activate dlt operon transcription since the resulting proteins are involved in cell shape (10) and, indirectly, in cell division. Despite the presence of autochthonous microbiota (32) and the stress generated by exposure to gastric acid and bile (12), the GI tract environment does not appear to impair the physiology of L. casei or its viability. However, the bacterium seems likely to carefully control promoter activity while transiting through the GI tract.

Several studies have recently investigated probiotic adaptation in the highly competitive ecosystem of the GI tract, and different approaches have been used to identify specific gene expressions. In vivo expression technology has been adapted to screen for specific in vivo-induced genes of Lactobacillus plantarum (4) and Lactobacillus reuteri (34) in the murine GI tract. Two-dimensional electrophoresis and DNA microarray studies, with methods adapted to GI contents (35), are promising approaches to identify the thousands of genes expressed simultaneously in vivo. The methods enable rapid identification of the functions activated in the gut, but they need to be combined with an accurate method for targeted studies. In such a context, the RT-QPCR approach developed in this study may be of value. The sensitivity of RT-QPCR has been shown to be superior to that of DNA microarrays (27) and may thus ensure detection of low-level gene expression.

The present study is the first to investigate a probiotic in a physiological state in the GI tract by direct transcription analysis of fecal samples. In line with previous studies, we have confirmed that L. casei can initiate protein synthesis during GI transit and that the bacterium modulates gene expression in a setting of physiological adaptation to environmental change. With a view to linking beneficial probiotic functions to new protein synthesis and obtaining specific information on probiotic adaptation, the RT-QPCR approach described herein, combined with other methods, is promising.


We are grateful to Donald White for correcting the English of the manuscript and to Jerome Combrisson, Denis Mater, and Olivier Goniak for their helpful advice.


1. Alpert, C. A., and U. Siebers. 1997. The lac operon of Lactobacillus casei contains lacT, a gene coding for a protein of the Bg1G family of transcriptional antiterminators. J. Bacteriol. 179:1555-1562. [PMC free article] [PubMed]
2. Bélanger, S. D., M. Boissinot, N. Clairoux, F. J. Picard, and M. G. Bergeron. 2003. Rapid detection of Clostridium difficile in feces by real-time PCR. J. Clin. Microbiol. 41:730-734. [PMC free article] [PubMed]
3. Borruel, N., M. Carol, F. Casellas, M. Antolin, F. de Lara, E. Espin, J. Naval, F. Guarner, and J. R. Malagelada. 2002. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51:659-664. [PMC free article] [PubMed]
4. Bron, P. A., C. Grangette, A. Mercenier, W. M. de Vos, and M. Kleerebezem. 2004. Identification of Lactobacillus plantarum genes that are induced in the gastrointestinal tract of mice. J. Bacteriol. 186:5721-5729. [PMC free article] [PubMed]
5. Corthier, G., C. Delorme, S. D. Ehrlich, and P. Renault. 1998. Use of luciferase genes as biosensors to study bacterial physiology in the digestive tract. Appl. Environ. Microbiol. 64:2721-2722. [PMC free article] [PubMed]
6. De Man, J. C., M. Rogosa, and M. E. Sharpe. 1960. A medium for the cultivation of lactobacilli. J. Appl. Bacteriol. 23:130-135.
7. Eaton, T. J., C. A. Shearman, and M. J. Gasson. 1993. The use of bacterial luciferase genes as reporter genes in Lactococcus: regulation of the Lactococcus lactis subsp. lactis lactose genes. J. Gen. Microbiol. 139:1495-1501. [PubMed]
8. Garcia, S., J. M. Crance, A. Billecocq, A. Peinnequin, A. Jouan, M. Bouloy, and D. Garin. 2001. Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds. J. Clin. Microbiol. 39:4456-4461. [PMC free article] [PubMed]
9. Gilson, T. J. 1984. Ph.D. thesis. University of Cambridge, Cambridge, England.
10. Heaton, M. P., and F. C. Neuhaus. 1992. Biosynthesis of d-alanyl-lipoteichoic acid: cloning, nucleotide sequence, and expression of the Lactobacillus casei gene for the d-alanine-activating enzyme. J. Bacteriol. 174:4707-4717. [PMC free article] [PubMed]
11. Huijsdens, X. W., R. K. Linskens, M. Mak, S. G. M. Meuwissen, C. M. J. E. Vandenbroucke-Grauls, and P. H. M. Savelkoul. 2002. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. J. Clin. Microbiol. 40:4423-4427. [PMC free article] [PubMed]
12. Kailasapathy, K., and J. Chin. 2000. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. Immunol. Cell Biol. 78:80-88. [PubMed]
13. Kolter, R., D. A. Siegele, and A. Tormo. 1993. The stationary phase of the bacterial life cycle. Annu. Rev. Microbiol. 47:855-874. [PubMed]
14. Lebourgeois, P. 1993. Ph.D. thesis. Université Paul Sabatier, Toulouse, France.
15. Mercenier, A., S. Pavan, and B. Pot. 2003. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr. Pharm. Des. 9:175-191. [PubMed]
16. Monedero, V., M. J. Gosalbes, and G. Perez-Martinez. 1997. Catabolite repression in Lactobacillus casei ATCC 393 is mediated by CcpA. J. Bacteriol. 179:6657-6664. [PMC free article] [PubMed]
17. Ntamere, A. S., D. J. Taron, and F. C. Neuhaus. 1987. Assembly of d-alanyl-lipoteichoic acid in Lactobacillus casei: mutants deficient in the d-alanyl ester content of this amphiphile. J. Bacteriol. 169:1702-1711. [PMC free article] [PubMed]
18. Oozeer, R., N. Goupil-Feuillerat, C. A. Alpert, M. van de Guchte, J. Anba, J. Mengaud, and G. Corthier. 2002. Lactobacillus casei is able to survive and initiate protein synthesis during its transit in the digestive tract of human flora-associated mice. Appl. Environ. Microbiol. 68:3570-3574. [PMC free article] [PubMed]
19. Ouwehand, A. C., S. Salminen, and E. Isolauri. 2002. Probiotics: an overview of beneficial effects. Antonie Leeuwenhoek 82:279-289. [PubMed]
20. Paubert-Braquet, M., X.-H. Gan, C. Gaudichon, N. Hedef, A. Serikoff, C. Bouley, B. Bonavida, and P. Braquet. 1995. Enhancement of host resistance against Salmonella typhimurium in mice fed a diet supplemented with yogurt or milks fermented with various Lactobacillus casei strains. Int. J. Immunother. 11:153-161.
21. Pedone, C. A., C. C. Arnaud, E. R. Postaire, C. F. Bouley, and P. Reinert. 2000. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int. J. Clin. Pract. 54:568-571. [PubMed]
22. Pedone, C. A., A. O. Bernabeu, E. R. Postaire, C. F. Bouley, and P. Reinert. 1999. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care centres. Int. J. Clin. Pract. 53:179-184. [PubMed]
23. Perego, M., P. Glaser, A. Minutello, M. A. Strauch, K. Leopold, and W. Fischer. 1995. Incorporation of D-alanine into lipoteichoic acid and wall teichoic acid in Bacillus subtilis. Identification of genes and regulation. J. Biol. Chem. 270:15598-15606. [PubMed]
24. Posno, M., R. J. Leer, N. van Luijk, M. J. F. van Giezen, P. T. H. M. Heuvelmans, B. C. Lokman, and P. H. Pouwels. 1991. Incompatibility of Lactobacillus vectors with replicons derived from small cryptic Lactobacillus plasmids and segregational instability of the introduced vectors. Appl. Environ. Microbiol. 57:1822-1828. [PMC free article] [PubMed]
25. Pouwels, P. H., A. Vriesema, B. Martinez, F. J. Tielen, J. F. Seegers, R. J. Leer, J. Jore, and E. Smit. 2001. Lactobacilli as vehicles for targeting antigens to mucosal tissues by surface exposition of foreign antigens. Methods Enzymol. 336:369-389. [PubMed]
26. Poyart, C., M. C. Lamy, C. Boumaila, F. Fiedler, and P. Trieu-Cuot. 2001. Regulation of d-alanyl-lipoteichoic acid biosynthesis in Streptococcus agalactiae involves a novel two-component regulatory system. J. Bacteriol. 183:6324-6334. [PMC free article] [PubMed]
27. Rajeevan, M. S., D. G. Ranamukhaarachchi, S. D. Vernon, and E. R. Unger. 2001. Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies. Methods 25:443-451. [PubMed]
28. Rokbi, B., D. Seguin, B. Guy, V. Mazarin, E. Vidor, F. Mion, M. Cadoz, and M. J. Quentin-Millet. 2001. Assessment of Helicobacter pylori gene expression within mouse and human gastric mucosae by real-time reverse transcriptase PCR. Infect. Immun. 69:4759-4766. [PMC free article] [PubMed]
29. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
30. Savijoki, K., and A. Palva. 1997. Molecular genetic characterization of the l-lactate dehydrogenase gene (ldhL) of Lactobacillus helveticus and biochemical characterization of the enzyme. Appl. Environ. Microbiol. 63:2850-2856. [PMC free article] [PubMed]
31. Shelburne, C. E., R. M. Gleason, G. R. Germaine, L. F. Wolff, B. H. Mullally, W. A. Coulter, and D. E. Lopatin. 2002. Quantitative reverse transcription polymerase chain reaction analysis of Porphyromonas gingivalis gene expression in vivo. J. Microbiol. Methods 49:147-156. [PubMed]
32. Simon, G. L., and S. L. Gorbach. 1986. The human intestinal microflora. Dig. Dis. Sci. 31(9 Suppl):147S-162S. [PubMed]
33. Thorne, S. H., and H. D. Williams. 1997. Adaptation to nutrient starvation in Rhizobium leguminosarum bv. phaseoli: analysis of survival, stress resistance, and changes in macromolecular synthesis during entry to and exit from stationary phase. J. Bacteriol. 179:6894-6901. [PMC free article] [PubMed]
34. Walter, J., N. C. K. Heng, W. P. Hammes, D. M. Loach, G. W. Tannock, and C. Hertel. 2003. Identification of Lactobacillus reuteri genes specifically induced in the mouse gastrointestinal tract. Appl. Environ. Microbiol. 69:2044-2051. [PMC free article] [PubMed]
35. Wang, R. F., M. L. Beggs, L. H. Robertson, and C. E. Cerniglia. 2002. Design and evaluation of oligonucleotide-microarray method for the detection of human intestinal bacteria in fecal samples. FEMS. Microbiol. Lett. 213:175-182. [PubMed]

Articles from Applied and Environmental Microbiology are provided here courtesy of American Society for Microbiology (ASM)
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...